文献速递肝病

优化使用非酒精性脂肪性肝病纤维化评分、纤维化-4评分和肝硬度检测识别进展性纤维化患者

Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients With Advanced Fibrosis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-03-12

该回顾性分析纳入亚洲9国10中心759例活检证实的非酒精性脂肪性肝病(24%有进展性纤维化)患者,评估两步法(纤维化评分后仅对不确定或高风险者行肝硬度检测)与单用肝硬度检测的准确性。在进展性纤维化低患病率人群中,两步法可减少不确定或 discordant 结果并降低肝硬度检测需求;在高患病率人群中,单用肝硬度≥10 kPa准确性最高。

要点

  • 在进展性纤维化患病率3.7%和10%人群中,两步法(NFS后肝硬度,灰区10-15 kPa)不确定或 discordant 结果分别为6.9%和7.9%,误分类分别为2.7%和6.6%。
  • 上述低患病率人群中仅25.6%和27.4%患者需肝硬度检测。
  • 在患病率24%和50%人群中,单用肝硬度≥10 kPa准确性最高,误分类分别为18.1%和18.3%。

核心结论

  • 回顾性分析发现,两步法(纤维化评分后行肝硬度检测)在进展性纤维化低患病率人群中能最准确识别进展性纤维化。
  • 在进展性纤维化高患病率人群中,肝硬度≥10 kPa识别进展性纤维化的准确性最高。

研究设计与样本

  • 回顾性分析,纳入2006年至2018年亚洲9国10中心759例活检证实的非酒精性脂肪性肝病患者,其中24%有进展性纤维化。
  • 以肝活检为参考标准,计算单用或联用纤维化评分(NFS或FIB-4)与肝硬度检测的误分类及不确定或 discordant 结果百分比。
  • 分析重复用于随机选择的进展性纤维化患病率不同的亚组(组织学纤维化分期≥F3)。

主要发现

  • 在进展性纤维化患病率3.7%和10%的人群中,两步法(NFS后仅对不确定或高NFS者行肝硬度,灰区10-15 kPa)不确定或 discordant 结果为6.9%和7.9%,误分类为2.7%和6.6%,仅25.6%和27.4%患者需肝硬度检测。
  • 在进展性纤维化患病率24%和50%的人群中,单用肝硬度≥10 kPa诊断进展性纤维化准确性最高,误分类分别为18.1%和18.3%。
  • 以FIB-4替代NFS时结果相似。

关键数值与推荐

  • 两步法:先测NFS,仅对NFS不确定或高风险者行肝硬度检测,肝硬度灰区为10-15 kPa。
  • 单用肝硬度诊断进展性纤维化的阈值为≥10 kPa。

临床怎么用

  • 在进展性纤维化低患病率人群中,采用纤维化评分后行肝硬度检测的两步法可减少不确定或 discordant 结果并降低肝硬度检测需求。
  • 在进展性纤维化高患病率人群中,单用肝硬度≥10 kPa识别进展性纤维化准确性最高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Measuring liver stiffness only in patients with indeterminate or high nonalcoholic fatty liver disease (NAFLD) fibrosis scores (called a 2-step approach) was reported to reduce indeterminate or discordant results while maintaining the accuracy to identify patients with advanced fibrosis. We aimed to validate this approach using data collected from the Gut and Obesity in Asia Workgroup. METHODS: We performed a retrospective analysis of data from 759 patients with biopsy-proven NAFLD (24% with advanced fibrosis), seen at 10 centers in 9 countries in Asia, from 2006 through 2018. By using liver biopsies as the reference standard, we calculated percentages of misclassifications and indeterminate or discordant results from assessments made based on fibrosis scores (NAFLD fibrosis score [NFS] or Fibrosis-4 score) and liver stiffness measurements (LSMs), alone or in combination. The analysis was repeated using randomly selected subgroups with a different prevalence of advanced fibrosis (histologic fibrosis stage ≥F3). RESULTS: In groups in which 3.7% and 10% of patients had advanced fibrosis, a 2-step approach (using the NFS followed by LSM only for patients with indeterminate or high NFS) and using a gray zone of 10 to 15 kPa for LSM, produced indeterminate or discordant results for 6.9% of patients and misclassified 2.7% of patients; only 25.6% of patients required LSM. In the group in which 10% of patients had advanced fibrosis, the same approach produced indeterminate or discordant results for 7.9% of patients and misclassified 6.6% of patients; only 27.4% of patients required LSM. In groups in which 24% and 50% of patients had advanced fibrosis, using LSM ≥10 kPa alone for the diagnosis of advanced fibrosis had the highest accuracy and misclassified 18.1% and 18.3% of patients, respectively. These results were similar when the Fibrosis-4 score was used in place of NFS. CONCLUSIONS: In a retrospective analysis, we found that a 2-step approach using fibrosis scores followed by LSM most accurately detects advanced fibrosis in populations with a low prevalence of advanced fibrosis. However, LSM ≥10 kPa identifies patients with advanced fibrosis with the highest level of accuracy in populations with a high prevalence of advanced fibrosis.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Chan WK, Treeprasertsuk S, Goh GB, et al. Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients With Advanced Fibrosis. Clin Gastroenterol Hepatol. 2019. PMID: 30876959. doi:10.1016/j.cgh.2019.03.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。